Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MBX-400 in Healthy Volunteers
NCT02454699Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2015
- Primary completion
- Apr 2017
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of filociclovir in cytomegalovirus infection (CMV) (4 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Frequency of clinical and laboratory adverse events and serious adverse events. Started Nov 2015; status: completed.
02
Drugs
filociclovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT02454699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02454699.